Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
125 hedge funds and large institutions have $978M invested in Arena Pharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 40 reducing their positions, and 19 closing their positions.
188% more call options, than puts
Call options by funds: $47.9M | Put options by funds: $16.6M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more capital invested
Capital invested by funds: $734M → $978M (+$244M)
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
13% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 40
5% more funds holding
Funds holding: 119 → 125 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$15.3M |
| 2 |
DM
Deerfield Management
New York
|
+$12.8M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.98M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$7.45M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$6.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$9.39M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$8.96M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.76M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$7.03M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.38M |
ARNA Hedge Fund Activity: Q4 2017 in Review
125 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2017, worth a combined $978M — up 33% from $734M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ARNA positions and 19 closed out — a net gain of 6 holders — while 45 added to existing stakes and 40 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $15.3M. The largest seller was Renaissance Technologies, cutting an estimated $9.39M.
- 125 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2017, up from 119 in Q3 2017.
- Funds reported $978M of Arena Pharmaceuticals Inc stock for Q4 2017, up 33% quarter-over-quarter.
- 25 funds opened new Arena Pharmaceuticals Inc positions in Q4 2017 and 19 closed out, a net change of +6 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q4 2017 was Alyeska Investment Group, an estimated $15.3M added.
- The largest Arena Pharmaceuticals Inc seller in Q4 2017 was Renaissance Technologies, an estimated $9.39M sold.
Based on aggregated 13F filings for Q4 2017.